Clinical Trial Update: Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII [Phase 4]

View source ↗

Summary

Phase 4 trial results evaluating a combination of low-dose recombinant factor VIIa (rFVIIa) and FEIBA in severe Hemophilia A patients with inhibitors to factor …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• FEIBA (activated prothrombin complex concentrate)
• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Sheba Medical Center | Conditions: Hemophilia A | Phase 4 | Status: COMPLETED